Document Detail


Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.
MedLine Citation:
PMID:  16603730     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chloride channels modulate gastrointestinal neuromuscular functions in vitro. Lubiprostone, a selective type 2 chloride channel (ClC-2) activator, induces intestinal secretion and has been shown to relieve constipation in clinical trials; however, the effects of lubiprostone on gastric function and whole gut transit in humans are unclear. Our aim was to compare the effects of the selective ClC-2 activator lubiprostone on maximum tolerated volume (MTV) of a meal, postprandial symptoms, gastric volumes, and gastrointestinal and colonic transit in humans. We performed a randomized, parallel-group, double-blind, placebo-controlled study evaluating the effects of lubiprostone (24 microg bid) in 30 healthy volunteers. Validated methods were used: scintigraphic gastrointestinal and colonic transit, SPECT to measure gastric volumes, and the nutrient drink ("satiation") test to measure MTV and postprandial symptoms. Lubiprostone accelerated small bowel and colonic transit, increased fasting gastric volume, and retarded gastric emptying. MTV values were reduced compared with placebo; however, the MTV was within the normal range for healthy adults in 13 of 14 participants, and there was no significant change compared with baseline measurements. Lubiprostone had no significant effect on postprandial gastric volume or aggregate symptoms but did decrease fullness 30 min after the fully satiating meal. Thus the ClC-2 activator lubiprostone accelerates small intestinal and colonic transit, which confers potential in the treatment of constipation.
Authors:
Michael Camilleri; Adil E Bharucha; Ryuji Ueno; Duane Burton; George M Thomforde; Kari Baxter; Sanna McKinzie; Alan R Zinsmeister
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of physiology. Gastrointestinal and liver physiology     Volume:  290     ISSN:  0193-1857     ISO Abbreviation:  Am. J. Physiol. Gastrointest. Liver Physiol.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-04-10     Completed Date:  2006-07-13     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  100901227     Medline TA:  Am J Physiol Gastrointest Liver Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  G942-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Alprostadil / adverse effects,  analogs & derivatives*,  pharmacology
Chloride Channels / physiology
Double-Blind Method
Fatty Acids / adverse effects,  pharmacology*
Female
Gastric Emptying / drug effects*
Gastrointestinal Transit / drug effects*
Humans
Male
Middle Aged
Placebos
Stomach / physiology*
Grant Support
ID/Acronym/Agency:
K24 DK 02638/DK/NIDDK NIH HHS; R01 DK 54681/DK/NIDDK NIH HHS; R01 DK 67071/DK/NIDDK NIH HHS; R01 HD 38666/HD/NICHD NIH HHS; RR 00585/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Chloride Channels; 0/Fatty Acids; 0/Placebos; 7662KG2R6K/lubiprostone; F5TD010360/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
Next Document:  Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitr...